drugset / Trial / NCT00584857

A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer

NCT00584857

Phase 2 Completed 30 enrolled University of Alabama at Birmingham
NaSingle-groupOpen-labelTreatment

Summary

This is a study to determine the optimal treatment for patients with advanced stage or recurrent endometrial cancer. Traditionally, patients have been treated with either hormonal therapies (megesterol) or chemotherapy (paclitaxel and carboplatin). This study investigates the effectiveness of the combination of hormonal therapy and chemotherapy. This study also will examine the side-effects associated with these drugs and the quality of life of patients on combination therapy.

Timeline

Start
2004-07
Primary completion
2010-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 6 unknown
Subject Megestrol Acetate Other / unclassified 40 mg Oral
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications